Research in mice suggests these molecules could treat cervical, breast, ovarian, and lung cancers

A new family of molecules that kill cancer cells and protect healthy cells could be used to treat a number of different cancers, including cervical, breast, ovarian and lung cancers.

Research published in EBioMedicine shows that as well as targeting and killing cancer cells, the molecules generate a protective effect against toxic chemicals in healthy cells.

Cells can become cancerous when their DNA is damaged.

Many different things can cause DNA damage, including smoking, chemicals and radiation; understanding exactly what happens at the point of DNA damage can help scientists develop new cancer treatments.

By studying this mechanism, researchers from the University of Waterloo in Canada could identify new molecules that selectively target cancer cells.

The researchers studied the process of DNA damage using a sort of molecular filming technique called femtosecond time-resolved laser spectroscopy.

The technique is like a high-speed camera, which uses two pulses of light: one to start a reaction, and the other to monitor the way the molecules react.

This technique let researchers watch how molecules interact in real-time, revealing how cells become cancerous.

Researchers have been using femtosecond laser spectroscopy to study biological molecules for decades, in fields called femtochemistry and femtobiology.

More recently, this technique was fused with molecular biology and cell biology techniques to advance our understanding of human diseases, notably cancer, and how their treatments work.

This potential new field is being dubbed femtomedicine (FMD).

"We know DNA damage is the initial and crucial step in the development of cancer," said Professor Qing-Bin Lu, lead author of the study from the University of Waterloo, Canada.

"With the FMD approach we can go back to the very beginning to find out what causes DNA damage in the first place, then mutation, then cancer. FMD is promising as an efficient, economical and rational approach for discovering new drugs, as it can save resources required to synthesise and screen a large library of compounds."

Taking advantage of the FMD approach, Professor Lu and his colleagues discovered a new family of molecules called nonplatinum-based halogenated molecules, or FMD compounds.

These are similar to cisplatin - a drug used to treat ovarian, testicular, lung, brain and other cancers.

However, while cisplatin is highly toxic, the new FMD compounds are not harmful to normal cells.

When the FMD compounds enter a cancer cell, they react strongly and form reactive radicals, which cause the cell to kill itself.

When the FMD compounds enter a healthy cell, the cell starts to increase the amount of a protective molecule called glutathione (GSH) in the cell.

This protects the cell against chemical toxins, so it is not damaged.

The researchers tested the molecules on human cells and in mice, and found very consistent results.

They treated human cells - various normal and cancer cells - with the FMD compounds and tested them to see whether the cells were killed.

They also tested the levels of GSH in the cells, revealing that the amount of protective molecule increased in the normal cells, while it decreased in cancer cells.

They then tested the FMD compounds on a range of tumours in mice, representing cervical, ovarian, breast and lung cancers.

They measured the extent to which the FMD compounds slowed down tumour growth, and found it was effective at slowing or halting the growth of all tumours.

"We're very excited about our discovery; we can see that the FMD compounds are just as effective as cisplatin in mice but without being toxic," said Professor Lu.

"We believe that it could potentially be used to treat a very wide rage of cancers, without making patients suffer the toxic side effects that some existing drugs have."

"We want this discovery to help patients, and we plan to move it into clinical trials as soon as possible," added Professor Lu.

Source: Elsevier